Apnimed 10-Q: $29.5M Q3 Loss, $351.8M Cash, and a Material Weakness in Controls
APMD sits 22% above its 52-week low of $13.88.
Summary
Apnimed's Q3 10-Q shows a $29.5 million net loss on launch spending, $351.8 million in cash that funds operations into Q2 2028, and a newly detailed material weakness in internal controls tied to the Q2 restatement.
Key Events · Earnings and Guidance · APMD
-
Q3 Loss Widens on Launch Spend
Net loss was $29.5 million for the quarter ended September 30, 2026, versus $10.9 million a year earlier, as G&A rose to $22.6 million from $6.0 million and R&D rose 21% to $11.8 million.
-
Material Weakness in Controls Disclosed
Management concluded disclosure controls were not effective at September 30, 2026 due to a material weakness: an ineffective control environment, insufficient IT access and change-management controls, and too few accounting personnel for complex transactions.
-
Restatement Still Being Assessed
The Q2 2026 10-Q/A reclassified the $85.4 million SASS gain into discontinued operations; management is assessing the effect of that restatement on internal control over financial reporting and disclosure controls.
-
Cash Funds Operations Into Q2 2028
$351.8 million in cash and cash equivalents at September 30, 2026 is expected to fund operations into the second quarter of 2028, beyond the February 28, 2027 PDUFA goal date for Oxnimbi.
Analysis · APMD · Life Sciences
The quarter itself is the story investors already saw this morning: spending on the Oxnimbi launch pushed the net loss to $29.5 million from $10.9 million a year earlier, with G&A jumping to $22.6 million from $6.0 million. What the 10-Q adds is a governance problem. Management concluded disclosure controls were not effective at September 30, 2026 because of a material weakness in internal control over financial reporting — an ineffective control environment, weak IT access and change-management controls, and too few accounting staff for complex transactions. That weakness sits alongside the previously disclosed restatement that moved the $85.4 million SASS gain into discontinued operations, and management is still assessing the restatement's effect on controls. Against that, the balance sheet is strong: $351.8 million in cash is expected to fund operations into the second quarter of 2028, well past the February 28, 2027 FDA decision date for Oxnimbi. The cash removes near-term financing risk; the control failures raise the odds of another reporting error and give regulators and investors a reason to discount reported numbers.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APMD was trading at $16.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $704.4M. The 52-week trading range was $13.88 to $35.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.